HumanOptics AG has received health insurance approval for its artificial iris Customflex ArtificialIris in the United States. Approval by the state Centers for Medicare and Medicaid Services (CMS) as a reimbursable medical product ensures that costs are covered by health insurance and is an important prerequisite for patients to decide in favor of treatment, according to a company news release.
With Customflex ArtificialIris, HumanOptics is the only company whose artificial iris has been approved for the US market by the FDA. As a result of the additional health insurance approval now granted retroactively to January 1, 2020, more patients in the United States will have access to this unique therapy.
The Customflex ArtificialIris is used for patients who have partially or completely lost their iris due to an accident or who have no or uncomplete iris from birth. Such a defect is very stressful in everyday social life, leads to complaints such as severe light sensitivity or loss of vision and increases the risk of other eye diseases such as glaucoma and cataract. The high-quality implant replaces the completely or partially missing or damaged iris.
Each Customflex ArtificialIris is individually manufactured by HumanOptics after the original appearance of the patient’s iris. It consists of a flexible silicone material which is inserted into the eye in a well-tolerated manner by means of a small incision technique.